Danish Pharma Stock News

Vestas Wind Systems (CPSE:VWS) has attracted fresh attention after disclosing new turbine orders across Europe, North America, and Australia, covering more than 1,000 MW of capacity under long term service agreements. See our latest analysis for Vestas Wind Systems. These multi region turbine orders arrive after a strong run in the shares, with a 90 day share price return of 41.07% and a 1 year total shareholder return of 93.52%. However, the 3 and 5 year total shareholder returns of 14.36%...

A U.S. federal judge recently cleared Danish offshore wind developer Ørsted to resume work on its nearly completed, US$5.00 billion Revolution Wind project off Rhode Island and Connecticut, overturning a Trump administration halt that cited national security concerns. The ruling materially reduces the risk of cancellation for a major U.S. offshore wind asset, reinforcing the legal and regulatory contours shaping Ørsted’s American growth ambitions. We’ll now examine how the court’s reversal...

Novo Nordisk has launched its FDA-approved oral Wegovy pill in the U.S., rapidly widening access through major pharmacies, Amazon Pharmacy, and telehealth platforms as the first GLP-1 pill for chronic weight management and cardiovascular risk reduction. This shift toward a once-daily pill, backed by phase 3 data and expanding distribution partnerships, could materially influence how patients choose between oral and injectable GLP-1 therapies in obesity care. We’ll now examine how the broad...

In recent months, GN Store Nord A/S has been working to rebuild its position in audio and hearing technology by tightening costs, integrating operations more effectively, and continuing to develop its Jabra and hearing-aid product lines. This quieter turnaround effort matters because it ties GN’s professional and medical audio strengths directly to persistent trends in remote work and age-driven hearing care demand. We’ll now examine how GN Store Nord’s renewed emphasis on cost savings and...

Danske Bank has continued its DKK 5.00 billion share buy-back programme, having repurchased 18,155,560 shares so far, while also appointing Dr Fiona Browne as its first Head of AI to lead a new AI centre of excellence in Belfast. Together, the ongoing buy-back and creation of a dedicated AI leadership role highlight Danske Bank’s twin focus on capital return discipline and building in-house technological capabilities. We’ll now examine how the expanding share buy-back and new AI centre of...

Those holding Shape Robotics A/S ( CPH:SHAPE ) shares would be relieved that the share price has rebounded 26% in the...

Alm. Brand A/S previously announced a share buy-back program of up to DKK 835.2 million under EU Safe Harbour regulations and now holds 42,210,970 own shares, equal to 2.91% of its outstanding share capital. This sizeable buy-back signals a clear focus on capital return, which may influence how investors view Alm. Brand’s balance between growth and distributions. We’ll now examine how this sizeable buy-back program shapes Alm. Brand’s existing investment narrative around capital allocation...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

To the annoyance of some shareholders, cBrain A/S ( CPH:CBRAIN ) shares are down a considerable 26% in the last month...

SP Group A/S ( CPH:SPG ) shares have continued their recent momentum with a 26% gain in the last month alone. The last...

A.P. Møller - Mærsk has appointed Ditlev Blicher as Regional President for North America and reassigned Charles van der Steene to lead the India, Middle East and Africa region, with both leadership changes effective from January 1, 2026. The reshuffle places executives with deep experience in Asia-Pacific and prior IMEA operations into two of Maersk’s most operationally complex growth regions, potentially influencing how its integrated logistics model is executed on the ground. We’ll now...

Novo Nordisk (CPSE:NOVO B) is in focus after the U.S. launch of its FDA approved Wegovy pill, the first oral GLP-1 for chronic weight management. The product is quickly rolling out across major retail and telehealth channels. See our latest analysis for Novo Nordisk. Investors appear to be reacting to the Wegovy pill launch and rapid distribution agreements, with a 30 day share price return of 18.78% and a year to date share price return of 15.50%. The 1 year total shareholder return of a...

With a price-to-earnings (or "P/E") ratio of 41.9x DSV A/S ( CPH:DSV ) may be sending very bearish signals at the...

Pandora (CPSE:PNDORA) cut its 2025 sales growth forecast to 6% after weaker than expected US holiday spending, while shares dropped 10% as the new CEO highlighted soft North American sentiment and rising silver costs. See our latest analysis for Pandora. The 13% one day share price decline and 26.3% 90 day share price return, together with a 55% drop in one year total shareholder return, suggest momentum has been fading even though three and five year total shareholder returns remain...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Why TORM’s governance reset matters for shareholders TORM (CPSE:TRMD A) has just gone through a governance reset after Oaktree Capital Management’s stake fell below one third, removing special voting rights and putting the company on a simpler one share, one vote footing. The move also coincides with Deputy Chairman and Senior Independent Director David Weinstein stepping off the Board and shifting into a Special Advisor role. This keeps his experience connected to the company while formal...

You may be wondering if Pandora is starting to look like value after a tough run, or if the risks still outweigh the potential reward for you as a shareholder or watchlist follower. The stock last closed at DKK 588.4, after a 15.4% decline over 7 days, a 16.8% decline over 30 days, a 15.4% decline year to date and a 55.0% decline over the past year, while the 3 year and 5 year returns sit at 10.7% and 6.8% respectively. Recent price moves have come alongside ongoing market attention on...

Matas A/S ( CPH:MATAS ) shareholders might be concerned after seeing the share price drop 16% in the last quarter. But...

With a price-to-earnings (or "P/E") ratio of 12.7x Rockwool A/S ( CPH:ROCK B ) may be sending bullish signals at the...

Carlsberg (CPSE:CARL B) is back in focus after its Swiss subsidiary, Feldschlösschen, temporarily stopped deliveries to Migros Group due to a pricing dispute. This has disrupted beer and soft drink supply across several Swiss retail chains. See our latest analysis for Carlsberg. Carlsberg’s pricing stand off in Switzerland comes against a backdrop of solid recent momentum, with an 11.7% 90 day share price return and a 26.05% 1 year total shareholder return, while longer term gains have been...

In February 2025, Pandora launched an EU-compliant share buyback programme and, by 2 January 2026, had repurchased shares totalling DKK 4.00 billion to reduce share capital and meet incentive scheme obligations. This sizeable capital return and reduction in share count may influence how investors assess Pandora’s earnings profile and capital allocation priorities. We’ll now explore how the completed DKK 4.00 billion buyback, and its impact on share count, reshapes Pandora’s broader...

Key Insights Significant control over UIE by private companies implies that the general public has more power to...

TORM plc recently confirmed that Oaktree Capital Management’s ownership has fallen below the one-third threshold, extinguishing the B-Director role, prompting Deputy Chairman and Senior Independent Director David Weinstein to leave the Board on January 6, 2026, while staying on as Special Advisor. Alongside this, TORM is redeeming and cancelling its B- and C-shares, simplifying its capital structure and consolidating voting power into 101,332,707 A-shares and a single remaining B-share until...